Cost-effectiveness profile, organizational implications and patient preferences on the use of exogenous TSH therapy (Thyrogen®) vs. THW in thyroid residue ablation in Italy. FE [Internet]. 2016 Oct. 7 [cited 2025 Oct. 29];17(3). Available from: https://journals.seedstm.com/index.php/FE/article/view/1264